Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.

Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated EGFR amino acid sequence with a E746-A750 deletion. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: An irradiation system (100) comprises a plurality of irradiation devices (1) and a control device (2). The plurality of irradiation devices (1) are arranged adjacent to one another in a first direction. Each of the plurality of irradiation devices (1) is able to move an electromagnetic wave in a second direction different from the first direction while moving the electromagnetic wave in the first direction. The control device (2) controls the plurality of irradiation devices. Specifically, the control device (2) separates an irradiation position of the electromagnetic wave of each of the plurality of irradiation devices (1) from the control device by at least a predetermined distance or more in the second direction at a predetermined timing.

Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a HLA-A3 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the disclosure are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: An electromagnetic wave from a transmitter (100) is emitted toward the outside of a first angular range (AR). A receiver (200) cannot detect an electromagnetic wave reflected at a position somewhat close to a sensor device (10), specifically, an electromagnetic wave reflected at a position apart from the sensor device (10) by less than a distance R1. Specifically, when the electromagnetic wave is reflected at the position apart from the sensor device (10) by less than the distance R1, the electromagnetic wave reaches the sensor device (10) before the first angular range (AR) reaches a Y axis. Consequently, the electromagnetic wave reflected at the position somewhat close to the sensor device (10) is not detected by the receiver (200).

Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the disclosure are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: An information output method in which a computer is made execute processing includes acquiring a character string corresponding to identification information representing a product when the identification information representing the product is acquired, collecting information including the character string, referring to a storage configured to store a forbidden word corresponding to the character string, specifying information that does not include the forbidden word corresponding to the character string among the information that are collected, and outputting the information that does not include the forbidden word corresponding to the character string.

Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

Abstract: The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

Abstract: A liquid crystal display device has a semiconductor substrate. A plurality of switching elements are arranged on the substrate in matrix, and a plurality of pixel electrodes are provided above the switching elements, arranged in matrix corresponding to the switching elements. A liquid crystal layer is provided on the pixel electrodes. The switching element is connected with a corresponding pixel electrode by a wiring layer. Dummy layers are provided in the same level as the wiring layer so that a surface of the dummy layer is substantially flush with a surface of the wiring layer.

Abstract: In a keyless entry control apparatus having a fault diagnosis unit provided separately from a car and a keyless entry C/U, the fault diagnosis unit transmits a signal to each control unit connected to a communication line, and when receiving a communication enabling signal transmitted from the keyless entry C/U, the fault diagnosis unit can communicate with the keyless entry C/U. In the case where ID codes are entered in the keyless entry C/U, a signal for setting the keyless entry C/U to ID entry mode is transmitted from the fault diagnosis unit to the keyless entry C/U. The keyless entry C/U which received the signal is set to ID entry mode, and transmits entry information of the ID codes entered in an EEPROM to the fault diagnosis unit immediately. The entry information is displayed on a display device of the fault diagnosis unit.

Abstract: The number of vertical scanning in one field of a video signal is detected, and the number of scanning lines pulses at each row electrode of a liquid crystal display is determined in accordance with the difference between the determined number of vertical scanning lines number and the number of the row electrodes. The determined number of scanning pulses is stored in a retrace line interval. Scanning pulses are applied to the corresponding row electrode in a scanning interval. The number of row electrodes to which the scanning pulses are applied is the stored number of scanning pulses.